SNP specialist DxS raises funds to grow business:
This article was originally published in Clinica
DxS, the Manchester, UK business that was formed by ex-AstraZeneca managers to commercialise proprietary technology to identify single nucleotide polymorphisms in individuals' DNA, has raised some £1m ($1.8m) in a second round of funding. The financing, which was led by Northern Venture Managers (of Newcastle, Reading and Edinburgh), will help DxS expand its in-house testing service for pharmaceutical companies and clinical research organisations, and also broaden its programme of licensing out the Scorpions technology. Scorpions can help predict how a patient will respond to a drug.